MedTrace Logo

Checkpoint Inhibitor-induced Liver Injury

NCT04476563 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 160

Last updated 2026-03-24

No results posted yet for this study

Summary

In this multi-center prospective observational study, the investigators plan to identify the incidence and risk factors for checkpoint inhibitor-induced liver injury and characterize biochemical, genetic, immunological, and histological features associated with it.

Conditions

  • Immune-Mediated Hepatitis

Interventions

DIAGNOSTIC_TEST

Obtaining biological samples

Biological samples (blood, urine, stool). Liver tissue will be obtained from ChILI group when clinically indicated

Sponsors & Collaborators

  • Pfizer

    collaborator INDUSTRY

  • University of Nottingham

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-10-13
Primary Completion
2026-06-30
Completion
2026-06-30

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04476563 on ClinicalTrials.gov